Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts

Vertex Pharmaceuticals (VRTX) closed at $403.30 in the latest trading session, marking a -1.36% move from the prior day. This change lagged the S&P 500's 0.01% gain on the day. On the other hand, the Dow registered a gain of 0.51%, and the technology-centric Nasdaq decreased by 0.28%. Prior to today's trading, shares of the drugmaker had gained 3% lagged the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83%.Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company's earnings per share (EPS) are projected to be $4.56, reflecting a 4.11% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $3.04 billion, up 9.78% from the prior-year quarter. For the annual period, the Zacks Consensus Estimates anticipate earnings of $17.98 per share and a revenue of $11.98 billion, signifying shifts of +4180.95% and +8.75%, respectively, from the last year. It is also important to note the recent changes to analyst estimates for Vertex Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold). In the context of valuation, Vertex Pharmaceuticals is at present trading with a Forward P/E ratio of 22.74. This valuation marks a premium compared to its industry average Forward P/E of 19.42. The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 74, positioning it in the top 30% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks